A combination of netupitant and palonosetron was non-inferior to aprepitant plus granisetron in preventing chemotherapy-induced nausea and vomiting.
A combination of netupitant and palonosetron (NEPA) was non-inferior to aprepitant plus granisetron (APR/GRAN) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC), according to a randomized phase III trial. The NEPA regimen required only one administration, vs 3 days with the APR/GRAN regimen.
Coadministration of antiemetics that can inhibit multiple pathways is needed to help control CINV in patients receiving HEC, according to Li Zhang, MD, of Sun Yat-Sen University Cancer Center in Guangzhou, China. Oral NEPA is the first antiemetic that combines a highly selective NK1 receptor agonist (netupitant) with a 5-HT3 receptor agonist (palonosetron); previously, no studies had directly compared regimens containing NK1 receptor agonists.
Zhang presented results of the new study, comparing NEPA with APR/GRAN, at the Multinational Association of Supportive Care in Cancer’s Annual Meeting, which was held June 22–24 in Washington, DC. The study included 829 patients undergoing cisplatin-based chemotherapy randomized to either NEPA (413 patients) or APR/GRAN (416 patients); the NEPA patients received the medication on day 1 of chemotherapy treatment, while those receiving APR/GRAN received APR on days 1, 2, and 3 and GRAN on day 1. All patients received oral dexamethasone on days 1–4.
Most patients were male (> 70% in each group), and the most common cancer type was lung, followed by head and neck malignancies.
A complete response (CR) was defined as no emesis, and no need for rescue medication during the overall phase (hours 0 to 120). The CR rate was 73.8% with NEPA, compared with 72.4% with APR/GRAN, which met the criteria for non-inferiority. In the acute period (0–24 hours), the CR rate was 84.5% with NEPA and 87.0% with APR/GRAN; in the delayed period (25–120 hours), those rates were 77.9% and 74.3%, respectively.
Zhang noted that though the overall CR rates were similar, the daily rates of patients experiencing CINV remained steady between 13% and 15% for APR/GRAN, while it declined from 16% to 8% over 5 days with NEPA. At day 5, this difference was significant (P = .0063).
The toxicity profiles of the regimens were similar; 58.1% of NEPA patients experienced at least one treatment-emergent adverse event, compared with 57.5% of APR/GRAN patients. Severe events occurred in 8.7% and 10.8% of those groups, respectively.
Zhang concluded that NEPA is at least as effective as APR/GRAN in cancer patients receiving HEC, and it carries the added convenience of a single capsule targeting multiple molecular pathways that can be administered only once per cycle.
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship
The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.